WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Neverfail
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Medical
Wugen | June 16, 2022
WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...
Industrial Impact
Moderna, Inc. | February 24, 2022
Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a trusted partner, bringing a ...
Industrial Impact, Medical
Businesswire | March 29, 2023
Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. “This collaboration builds on the groundbreaking clinical work we have been doing in the...
MedTech, Industry Outlook
PRNewswire | June 01, 2023
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabiliti...
Cell and Gene Therapy, Industrial Impact
Whitepaper
MedTech
Video
MedTech, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE